Prostate Cancer Treatments Clears Speculations Over Cure Rates

Prostate cancer is one of the leading causes of death among American men after lung cancer. Approximately 1 in 39 men die of prostate cancer. The disease can be serious in nature, but many diagnosed with the disease often survive highlights research analysts at Allied Market Research, studying the size and share of the ‘Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market’. As per American Cancer Society over 2.9 million men in the U.S who were diagnosed with the diseases at some points are alive. 

Hormone therapy coupled with radiotherapy minimizes deaths 
Recent studies have revealed that hormone therapy as well as radiotherapy form a perfect combination, when it comes to minimizing the risk of death in patients with prostate cancer. As per the follow-up research published in the popular journal “European Urology” the treatment can halve the risk even 15 years after the patient has been diagnosed with the disease. Anders Widmark, a reputed professor and senior physician at the famous Umea University, said “Before the turn of the century, it was tradition to castrate men with high-risk or aggressive local prostate cancer with no signs of spreading, as the disease at that point was thought to be incurable," Widmark is leading the study. Industry experts believe that such innovation will open new opportunities for Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market.

Immunotherapy sees more discoveries 
In 2016, prostate cancer immunotherapy has definitely taken a center stage, especially in the Pre-ASCO release. Big Pharma is again in the news! This time the company has surprised everyone by introducing the survival data. The response prior to the much awaited ASCO event to be held in June is definitely motivating. All drug-advancement events bear great significance, but there’s no event so closely assessed by prominent investors, medical practitioners and patients than the ASCO annual event. Drug makers are finally increasing their focus, when it comes to prostate cancer immunotherapies. This is one of the noteworthy developments in the Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market. 

Click here to read more market research reports on Pharmaceuticals Industry

Over the past decade, there has been a major shift in how pharmaceutical companies are treating the disease. For instance, prostate cancer is the second most commonly diagnosed cancer in men. The patient with the disease is believed to have a five-year survival rate in 90%. Industry experts are of the faith that the number is up from 1975 and 1977. During this period the five -year survival rates, particularly for prostate cancer was approximately 68 % as per the studies conducted by the American Cancer Society. 

Shorter radiation therapy gets acceptance 
According to a recent research shorter and highly intense radiation on patients with early stage cancer can be easily performed and doctors no longer have to compromise on the cancer control. At present, the standard procedure last for about eight weeks. But, the new research carried out by a team of experts at the famous Duke Cancer Institute is believed to have further shortened the regime to about 5.5 weeks. This research involved 1,100 men with early -stage cancer. The team of researchers compared the two therapies to identify the cure rates. While one half was assigned to 5.5 – week treatment the other half underwent an 8-week treatment.
Experts identified that the five – year cancer free survival rate was about 85.3% for those who underwent an eight – week trial. Men who received 5.5 – week program experienced a DFS rate of 86.3%. Besides this, the overall survival rate was almost similar between both the groups, 93.2 % as well as 92.5%, respectively. 

Drug delivery method experiences a major shift 
UGA Researchers surprised many when they discovered an effective therapy for prostate cancer. A team of researchers at the University of Georgia has finally designed a method to treat the disease. Industry experts outline that application of nanoparticle drug delivery system has often worried patients with prostate cancer. @UGAResearch say their aim is to inhibit PAK -1 a protein. Their enzyme when overexposed in cancer applying a drug called IPA3 is believed to reduce the tumour revealed Dr. Brain Cummings, an associate professor in biomedical and pharma science department. Commenting on the recent combination Cummings said “The treatment is actually a combination of a chemical that targets the enzyme that is shown to be overexposed.” To attain perfection Cumming has developed a nanoparticle to encapsulate and deliver drug. 

 

Related Post